Radius Health
NEWS
Ayala announced positive data for its desmoid tumor treatment, while Vertex and Dyne announced the FDA had lifted the hold on their clinical studies.
With the submission of NDAs and BLAs, multiple companies are bidding for regulatory approval of drug candidates. BioSpace takes a look at several of the latest requests.
Celebrities’ struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health’s elacestrant are on the horizon.
It was yet another busy week for clinical trial news. Here’s a look.
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Charles Morris, chief medical officer for Waltham, Mass.-based Radius Health, is eying the day that there will be better outcomes for breast cancer patients who have developed tumors resistant to current treatments. If things continue to go well, Radius may be able to provide those options.
Let’s take a look at who made a splash in the pharma and biotech world the past week.
JOBS
IN THE PRESS